Crinetics Pharmaceuticals (CRNX) Misses Q2 EPS by 7c

Crinetics Pharmaceuticals (NASDAQ: CRNX) reported Q2 EPS of ($0.94), $0.07 worse than the analyst estimate of ($0.87). Revenue for the quarter came in at $1 million versus the consensus estimate of $1.1 million.

For earnings history and earnings-related data on Crinetics Pharmaceuticals (CRNX) click here.

You May Also Be Interested In

• TJX stock drops as profit outlook falls short of analyst estimates
• Analog Devices (ADI) Tops Q3 EPS by 11c, Beats on Revenue; Offers Q4 Guidance
• UBS Reiterates Buy Rating on Gap, Inc. (GAP), Says Earnings Could Be a High-Volatility Event